Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Convertible Debt (2025 - 2026)

Cogent Biosciences' Convertible Debt history spans 2 years, with the latest figure at $223.2 million for Q1 2026.

  • Quarterly Convertible Debt changed N/A to $223.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $223.2 million through Mar 2026, changed N/A year-over-year, with the annual reading at $222.9 million for FY2025, N/A changed from the prior year.
  • Convertible Debt came in at $223.2 million for Q1 2026, roughly flat from $222.9 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $223.2 million in Q1 2026 to a low of $222.9 million in Q4 2025.